ACI
YMAB

AMP Capital Investors’s Y-mAbs Therapeutics YMAB Stock Holding History

AMP Capital Investors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,700
Closed -$233K – 1258
2021
Q1 		$233K Buy
+7,700
New +$316K ﹤0.01% 1141

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AMP Capital Investors's YMAB Position: Q2 2021 in Review

AMP Capital Investors sold out of Y-mAbs Therapeutics (YMAB) in Q2 2021, closing a stake of 7,700 shares — an estimated $233K sold.

AMP Capital Investors first reported a position in YMAB in Q1 2021 and held it in 1 quarter. The position peaked at $233K in Q1 2021. 100 funds tracked by Wall St. Rank hold YMAB as of Q2 2021.

  • AMP Capital Investors reported no remaining Y-mAbs Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AMP Capital Investors sold 7,700 Y-mAbs Therapeutics shares in Q2 2021, an estimated $233K.
  • AMP Capital Investors first reported a position in Y-mAbs Therapeutics in Q1 2021 and held it in 1 quarter.
  • AMP Capital Investors's Y-mAbs Therapeutics position peaked at $233K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2021.

Based on AMP Capital Investors's 13F filing for Q2 2021, filed 16 Aug 2021.